drugset / Trial / NCT04991480
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART4215 that can be given safely to participants alone and in combination with talazoparib * Learn more about the side effects of ART4215 alone and in combination with talazoparib * Learn more about the effectiveness of ART4215 alone and in combination with talazoparib * Learn more about the effectiveness of ART4215 alone and in combination with niraparib
Timeline
- Start
- 2021-09-13
- Primary completion
- 2025-12-24
- Completion
- 2025-12-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ART4215 | Unknown | — | Oral |
| Subject | Niraparib | Small molecule | 200 mg | Oral |
| Subject | Niraparib | Small molecule | 300 mg | Oral |
| Subject | Talazoparib | Small molecule | 0.75 mg | Oral |
| Subject | Talazoparib | Small molecule | 1 mg | Oral |